Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.52 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.52 |
| ▸ | ALB | P02768 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.52 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.52 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | MTOR | P42345 | 1/20 | 0.48 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.48 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.48 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.48 |
| ▸ | NT5E | P21589 | 1/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.46 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.46 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.44 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.44 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28796614 | 1.00 | LMNA (0.52) | LMNAPDE3ACACNA1FALBMAPT | |
| SCHEMBL28799641 | 0.89 | POLB (0.53) | LMNAPDE3ACACNA1FALBMAPT | |
| SCHEMBL5666376 | 0.89 | POLB (0.53) | LMNAPDE3ACACNA1FALBMAPT | |
| SCHEMBL10590097 | 0.88 | POLB (0.48) | LMNAPDE3ACACNA1FALBMAPT | |
| SCHEMBL5413908 | 0.87 | POLB (0.46) | LMNAPDE3ACACNA1FALBMAPT | |
| SCHEMBL3449196 | 0.87 | POLB (0.51) | LMNAPDE3ACACNA1FALBMAPT | |
| SCHEMBL7794947 | 0.87 | POLB (0.51) | LMNAPDE3ACACNA1FALBMAPT | |
| SCHEMBL5615379 | 0.86 | POLB (0.47) | LMNAPDE3ACACNA1FALBMAPT | |
| SCHEMBL127179 | 0.86 | POLB (0.50) | LMNAPDE3ACACNA1FALBMAPT | |
| SCHEMBL51649 | 0.86 | POLB (0.50) | LMNAPDE3ACACNA1FALBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12605397-B2 | Deoxy-cytidine or uridine derivatives for use in cancer therapies | TETRAGON BIOSCIENCE LTD. (IL) | 2026-04-21 | — | — | US | disclosed |
| EP-4591940-A2 | DEOXY- CYTIDINE DERIVATIVES FOR USE IN CANCER THERAPIES | Hemispherian AS (NO) | 2025-07-30 | — | — | EP | disclosed |
| EP-4233879-B1 | DEOXY- CYTIDINE DERIVATIVES FOR USE IN CANCER THERAPIES | HEMISPHERIAN AS (NO) | 2025-07-23 | — | — | EP | disclosed |
| US-20240216415-A1 | DEOXY-CYTIDINE OR URIDINE DERIVATIVES FOR USE IN CANCER THERAPIES | TETRAGON BIOSCIENCES LTD. (IL) | 2024-07-04 | — | — | US | disclosed |
| US-11963973-B2 | Deoxy-cytidine or uridine derivatives for use in cancer therapies | HEMISPHERIAN AS (NO) | 2024-04-23 | — | — | US | disclosed |
| CN-113543789-B | Deoxycytidine or uridine derivatives for use in cancer treatment | 赫米斯弗连有限公司 | 2024-04-05 | — | — | CN | disclosed |
| EP-4233879-A1 | DEOXY- CYTIDINE DERIVATIVES FOR USE IN CANCER THERAPIES | Hemispherian AS (NO) | 2023-08-30 | — | — | EP | disclosed |
| EP-3917538-B1 | DEOXY- CYTIDINE DERIVATIVES FOR USE IN CANCER THERAPIES | HEMISPHERIAN AS (NO) | 2023-07-12 | — | — | EP | disclosed |
| US-20220117992-A1 | DEOXY-CYTIDINE OR URIDINE DERIVATIVES FOR USE IN CANCER THERAPIES | TETRAGON BIOSCIENCES LTD. (IL) | 2022-04-21 | — | — | US | disclosed |
| EP-3917538-A1 | DEOXY- CYTIDINE OR URIDINE DERIVATIVES FOR USE IN CANCER THERAPIES | Hemispherian AS (NO) | 2021-12-08 | — | — | EP | disclosed |
| WO-2020157335-A1 | DEOXY- CYTIDINE OR URIDINE DERIVATIVES FOR USE IN CANCER THERAPIES | HEMISPHERIAN AS (NO) | 2020-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220117992-A1 | DEOXY-CYTIDINE OR URIDINE DERIVATIVES FOR USE IN CANCER THERAPIES | UMPS, UPP1, TYMP | LMNA 1802/4885PDE3A 1205/4885CACNA1F 4830/4885 |
| US-11963973-B2 | Deoxy-cytidine or uridine derivatives for use in cancer therapies | UMPS, UPP1, TYMP | LMNA 1802/4885PDE3A 1205/4885CACNA1F 4830/4885 |
| US-20240216415-A1 | DEOXY-CYTIDINE OR URIDINE DERIVATIVES FOR USE IN CANCER THERAPIES | UMPS, UPP1, TYMP | LMNA 1799/4885PDE3A 1218/4885CACNA1F 4838/4885 |
| US-12605397-B2 | Deoxy-cytidine or uridine derivatives for use in cancer therapies | CDA, DCTD, RNMT | LMNA 1542/4885PDE3A 1156/4885CACNA1F 3699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.